Teleflex Inc Stock Price, News & Analysis

Teleflex announced a quarterly cash dividend of $0.34 per share, payable on December 15, 2022 to shareholders on record by November 15, 2022. This decision underscores the company’s commitment to shareholder returns while continuing its focus on providing medical technologies that enhance patient care.

Teleflex announced Q3 2022 financial results with revenues of $686.8 million, representing a 1.9% decline year-over-year, partially offset by a 2.4% increase in constant currency. GAAP diluted EPS dropped to $2.16 from $4.20 in the prior year. The company lowered its GAAP revenue growth guidance to (0.75)% to 0.25% and adjusted diluted EPS guidance to $12.80 to $13.20. The acquisition of Standard Bariatrics aligns with its M&A strategy, contributing to revenue and margin growth.

Teleflex (NYSE: TFX) announced results from a new study published in the Journal of Endourology demonstrating that the UroLift^® System is effective for treating benign prostatic hyperplasia (BPH), specifically in patients with obstructive median lobes. Compared to TURP, patients treated with UroLift experienced significantly greater symptom improvement, faster satisfaction, and fewer post-op catheterizations. The analysis combined outcomes from controlled trials and real-world settings, confirming the safety and effectiveness of the UroLift System.

Teleflex (NYSE: TFX) will hold a conference call on October 27, 2022, at 8:00 a.m. ET to discuss its third-quarter financial results and operational updates. Participants can pre-register via the provided link or join via a live audio webcast on the company’s website. An audio replay will be accessible after 11:00 a.m. ET on the same day. Teleflex specializes in medical technologies that enhance health outcomes, with a diverse portfolio spanning vascular access, anesthesia, and surgical care.

Teleflex Incorporated has successfully acquired Standard Bariatrics, Inc. for $170 million, with potential additional payments of up to $130 million based on commercial milestones. This acquisition aims to enhance Teleflex's product offerings in bariatric surgery via advanced powered stapling technology. Notably, while the transaction is not expected to materially impact revenue for 2022 and is estimated to dilute adjusted earnings per share by approximately $0.10, it is projected to generate $30-$35 million in revenue for 2023, with further accretive effects on revenue and earnings thereafter.

Teleflex Incorporated (NYSE: TFX) has launched its new Arrow^® Pressure Injectable Midline portfolio in the US and Canada as of September 27, 2022. This portfolio includes the Arrowg+ard Blue Advance^® Midline designed to enhance patient safety by reducing confusion in line identification, which can lead to medication errors. With 14 kit configurations and features such as antimicrobial protection and eye-catching labeling, it aims to improve procedural efficiency. The innovation stems from collaboration with vascular access professionals.

Teleflex Incorporated (NYSE: TFX) announced the successful findings from the largest real-world evaluation of the MANTA® Device, presented by Dr. Magnus Settergren at the Transcatheter Cardiovascular Therapeutics (TCT) conference. The study, involving 1,048 subjects, showed a 4.2% major vascular complication rate, consistent with previous studies. The MANTA® Device, with over 100,000 units sold globally, is recognized for its safety, effectiveness, and short learning curve, enhancing its applicability in vascular closure for transcatheter aortic valve implantations.

Teleflex Incorporated (NYSE: TFX) will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 14, 2022, at 10:00 a.m. ET. The speech will be delivered by Liam Kelly, the Chairman, President, and CEO of Teleflex. A live audio webcast of the presentation will be available on the investor section of the Teleflex website. Teleflex specializes in medical technologies that enhance health and quality of life, focusing on innovations in various fields such as vascular access and anesthesia.

Teleflex (NYSE: TFX) has partnered with FundamentalVR to launch a virtual reality (VR) training platform for its UroLift® 2 System, targeting the treatment of benign prostatic hyperplasia (BPH). The platform allows urologists globally, including in newly approved markets like Japan, to practice procedures remotely with tactile feedback and realistic simulations. The training solution aims to improve clinical education access and standardization. Teleflex's UroLift® System is recognized for its minimally invasive approach and lack of new onset erectile dysfunction, benefiting over 350,000 men worldwide.